{"id":"W2967569980","doi":"10.1200/jco.19.01492","title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Nivolumab; Adverse effect; Transplantation; Oncology; Lymphoma; Anaplastic large-cell lymphoma; Gastroenterology; Surgery; CD30; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002654813,0.0002686539,0.001942837,0.00005953384,0.0001657098,0.00001831433,0.0002215499,0.0002622866,0.0001095535],"category_scores_gemma":[0.0008956703,0.000140835,0.0003517767,0.00009636751,0.0001727664,0.0001165416,0.000139535,0.0004661229,0.00002103298],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003125635,"about_ca_system_score_gemma":0.001692976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003141859,"about_ca_topic_score_gemma":0.00004275124,"domain_scores_codex":[0.996359,0.0004603419,0.001964479,0.000369643,0.0004926401,0.0003539342],"domain_scores_gemma":[0.9896281,0.007511513,0.00175919,0.0003734715,0.0003345093,0.0003932655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1866348,0.260311,0.3191821,0.00007475218,0.002406219,0.001134826,0.001247655,0.000002432735,0.0001598984,0.00004839817,0.007705924,0.221092],"study_design_scores_gemma":[0.3349209,0.1362901,0.4898044,0.0001168061,0.001339802,0.0001132569,0.0003933049,0.00004841363,0.00002847464,0.00002130996,0.03681727,0.0001059481],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916607,0.001058839,0.00003365277,0.00389164,0.001005698,0.001526877,0.00004803556,0.00001481278,0.0007597608],"genre_scores_gemma":[0.995369,0.0004595938,0.001048292,0.001984849,0.0007625261,0.00002482383,0.00003613006,0.0000337687,0.0002809969],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.220986,"threshold_uncertainty_score":0.5743086,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04362826385976647,"score_gpt":0.3842308283635864,"score_spread":0.3406025645038199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}